Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor

Nat Cancer. 2023 Jun;4(6):809-811. doi: 10.1038/s43018-023-00583-2. Epub 2023 Jun 15.

Authors

Jose Silva¹, Jiyang Yu², Kevin Kalinsky³

Affiliations

¹ Department of Pathology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA. jose.silva@mssm.edu.
² Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
³ Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.

PMID: 37322366
DOI: 10.1038/s43018-023-00583-2

No abstract available

Publication types

Letter
Comment

MeSH terms

Hydroxamic Acids* / pharmacology
Pyrimidines* / pharmacology

Substances

ricolinostat
Hydroxamic Acids
Pyrimidines